Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP957978.RAqYgSYJhk-T9A4ihZHkmggeE1BHJ5gF7nY-eti-NK0zc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP957978.RAqYgSYJhk-T9A4ihZHkmggeE1BHJ5gF7nY-eti-NK0zc130_assertion type Assertion NP957978.RAqYgSYJhk-T9A4ihZHkmggeE1BHJ5gF7nY-eti-NK0zc130_head.
- NP957978.RAqYgSYJhk-T9A4ihZHkmggeE1BHJ5gF7nY-eti-NK0zc130_assertion description "[We also found that Ik6 variant and CRLF2 overexpression had an important role in dictating the prognosis of Ph-negative patients, which may be useful markers in guiding the treatment of ALL in the future, with tyrosine kinase inhibitors on the other hand reversing the fate of Ph-positive ALL patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP957978.RAqYgSYJhk-T9A4ihZHkmggeE1BHJ5gF7nY-eti-NK0zc130_provenance.
- NP957978.RAqYgSYJhk-T9A4ihZHkmggeE1BHJ5gF7nY-eti-NK0zc130_assertion evidence source_evidence_literature NP957978.RAqYgSYJhk-T9A4ihZHkmggeE1BHJ5gF7nY-eti-NK0zc130_provenance.
- NP957978.RAqYgSYJhk-T9A4ihZHkmggeE1BHJ5gF7nY-eti-NK0zc130_assertion SIO_000772 22297722 NP957978.RAqYgSYJhk-T9A4ihZHkmggeE1BHJ5gF7nY-eti-NK0zc130_provenance.
- NP957978.RAqYgSYJhk-T9A4ihZHkmggeE1BHJ5gF7nY-eti-NK0zc130_assertion wasDerivedFrom befree-2016 NP957978.RAqYgSYJhk-T9A4ihZHkmggeE1BHJ5gF7nY-eti-NK0zc130_provenance.
- NP957978.RAqYgSYJhk-T9A4ihZHkmggeE1BHJ5gF7nY-eti-NK0zc130_assertion wasGeneratedBy ECO_0000203 NP957978.RAqYgSYJhk-T9A4ihZHkmggeE1BHJ5gF7nY-eti-NK0zc130_provenance.